search
Back to results

Comparison of the Efficacy and Safety of Cardioneuroablation to Permanent Pacing in Patients With an Implanted Pacemaker for Symptomatic Bradycardia. (GENTLE-PACE)

Primary Purpose

Bradycardia, Syncope

Status
Not yet recruiting
Phase
Not Applicable
Locations
Poland
Study Type
Interventional
Intervention
Invasive electrophysiological study
Extracardiac vagal stimulation
Cardioneuroablation
Redo cardioneuroablation
Implantation of the implantable loop recorder
Pacemaker check
Implantable loop recorder check
Holter ECG
Anamnesis
Sponsored by
4th Military Clinical Hospital with Polyclinic, Poland
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Bradycardia focused on measuring cardioneuroablarion, functional bradycardia, pacemaker treatment discontinuation

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Patients who underwent pacemaker implantation before 50 years old due to sinus node and/or atrioventricular node dysfunction Positive response to atropine test Age between 18-65 years Signed informed consent to participate in the study Exclusion Criteria: Own heart rate <30/min Fainting after pacemaker therapy initiation Persistent and sustained atrial fibrillation History of myocarditis History of cardiac surgery History of ablation procedures Congenital heart defects Congenital atrioventricular block Neuromuscular and neurodegenerative diseases Indications for expanding the pacemaker system to ICD/CRT-D Pregnancy Renal insufficiency with GFR <30 ml/min/1.73m2

Sites / Locations

  • Mazowiecki Specialist Hospital
  • Medical University of Silesia

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Active Comparator

Arm Label

Group 1

Group 2

Group 3

Arm Description

Group 1 will undergo EPS, ECVS, CNA with continuation of PM therapy and ILR implantation. Two months later pacing rate, will be assessed. In addition, there will be a non-invasive assessment of the effectiveness of CNA. After another month, EPS and ECVS will be performed and a re-CNA if the ECVS does not show full parasympathetic denervation of the heart. For patients with ECVS-confirmed successful CNA, the pacemaker will be set to VVI or AAI 30/min. One month after the second invasive procedure, the pacing rate will be assessed. Patients with zero percentage of PM stimulation will be set to ODO/OVO/OAO-stimulation off mode. Patients will be monitored for the next 12 months. During the next 4 visits repeated every 3 months, patients in this group will undergo non-invasive assessment of the effectiveness of CNA and symptoms of bradycardia. At the 7th visit, patients in this group will be qualified to discontinue of the cardiac pacing treatment, with possible qualification for TLE.

Group 2 will undergo EPS and ECVS with continuation of PM therapy, ILR implantation, without CNA. Two months later pacing rate, will be assessed. After another month, EPS, ECVS and CNA will be made. For patients with ECVS-confirmed successful CNA, the pacemaker will be set to VVI or AAI 30/min. One month after the second invasive procedure, patients in this group will have their pacing rate assessed. Patients with zero percentage of PM stimulation will be set to ODO/OVO/OAO-stimulation off mode. Patients will be monitored for the next 12 months. During next 4 visits repeated every 3 months, patients in this group will undergo a non-invasive assessment of the effectiveness of CNA and symptoms of bradycardia. At the 7th visit, the qualification for discontinuation of cardiac pacing treatment will take place, with possible qualification for TLE.

Group 3 patients will only be observed for the duration of the study. The observation period will be 18 months. At subsequent visits 1, 3, 4, 6, 9, 12, 15 months after randomization, they will be assessed for the presence of MAS, paraMAS and assessment of the percentage of stimulation.

Outcomes

Primary Outcome Measures

Primary efficacy endpoints- Composite endpoint
Composite endpoint including: occurrence of non-traumatic loss of consciousness occurrence of symptoms of presyncope state determination in the loop recorder recording of events of asymptomatic bradycardia requiring permanent cardiac pacing, understood as: type II degree atrioventricular block and/or atrioventricular block of 2:1 or higher order and/or sinus bradycardia <40/min during the patient's wakefulness sinus pause >3 seconds during the patient's wakefulness
Primary safety endpoints- Composite endpoint
Composite endpoint including: death from any cause peri-procedural damage to cardiac or vascular structures requiring surgical intervention not resulting in death ischemic stroke not terminated by death symptomatic damage to the pulmonary veins symptomatic injury to the phrenic nerve de-electrode device-related infective endocarditis device lodge infection electrode dysfunction requiring electrode replacement BARC grade 2, 3 bleeding during postoperative anticoagulant therapy

Secondary Outcome Measures

Secondary efficacy endpoint
Occurrence of non-traumatic loss of consciousness
Secondary efficacy endpoint
Occurrence of syncope in the course of documented bradyarrhythmia
Secondary efficacy endpoint
Occurrence of symptoms of pre-fainting state
Secondary efficacy endpoint
Occurrence of presyncope in the course of documented bradyarrhythmia
Secondary efficacy endpoint
Determination in the loop recorder recording of events of asymptomatic bradycardia requiring permanent pacing of the heart, understood as: atrioventricular block type II and/or atrioventricular block of 2:1 or higher order and/or sinus bradycardia <40/min during the patient's wakefulness sinus pause >3 seconds during the patient's wakefulness
Secondary efficacy endpoint
Disabling permanent cardiac pacing at visit 3
Secondary efficacy endpoint
Demonstration of a statistically significant lower pacing rate in the group of patients undergoing CNA vs patients who continued PM therapy without CAN
Secondary efficacy endpoint
Qualification for removal of PM and TLE system
Secondary safety endpoint
Death from any cause
Secondary safety endpoint
Peri-procedural damage to cardiac or vascular structures requiring surgical intervention not resulting in death
Secondary safety endpoint
Ischemic stroke not terminated by death
Secondary safety endpoint
Symptomatic pulmonary venous injury
Secondary safety endpoint
Symptomatic phrenic nerve injury
Secondary safety endpoint
Asymptomatic phrenic nerve injury
Secondary safety endpoint
Electrodermal infective endocarditis
Secondary safety endpoint
PM implantation site infection
Secondary safety endpoint
Electrode dysfunction
Secondary safety endpoint
Occurrence of atrial tachyarrhythmias
Secondary safety endpoint
Development of symptoms of heart failure
Secondary safety endpoint
Symptoms of inadequate sinus tachycardia
Secondary safety endpoint
Hospitalization for any reason
Secondary safety endpoint
BARC grade 2, 3 bleeding during postoperative anticoagulant therapy

Full Information

First Posted
May 21, 2023
Last Updated
June 10, 2023
Sponsor
4th Military Clinical Hospital with Polyclinic, Poland
search

1. Study Identification

Unique Protocol Identification Number
NCT05896592
Brief Title
Comparison of the Efficacy and Safety of Cardioneuroablation to Permanent Pacing in Patients With an Implanted Pacemaker for Symptomatic Bradycardia.
Acronym
GENTLE-PACE
Official Title
A Multicenter, Randomized, Double-blind, Research Study comparinG the Efficacy and Safety of cardioneuroablaTion vs Permanent Pacing in Patients With an implantabLE PACEmaker for Symptomatic Bradycardia.
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
August 1, 2023 (Anticipated)
Primary Completion Date
July 31, 2029 (Anticipated)
Study Completion Date
July 31, 2029 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
4th Military Clinical Hospital with Polyclinic, Poland

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Background Sinus node dysfunction (SND) and atrioventricular block (AVB) are significant diagnostic and therapeutic problems. The primary method of their treatment is cardiac pacemaker implantation (PM). Although PM remains the main therapeutic approach for most patients with SND/AVB, long-term PM therapy can be associated with various limitations, complications, and the need for device and electrode replacement. There is increasing evidence for the effectiveness of an alternative approach to functional bradycardia associated with excessive vagal activation - cardioneuroablation (CNA). The method leads to the alleviation or complete resolution of bradycardia symptoms, as well as reflex syncope, providing an opportunity to discontinue PM therapy. Primary aims 1. Evaluation of the efficacy and safety of CNA as a therapy allowing for discontinuation of PM therapy in patients with SND or AVB. Secondary aims Evaluation of the efficacy and safety of CNA as a therapy allowing for the optimization of PM therapy in patients with SND and AVB. Development of a diagnostic algorithm allowing for the identification of patients with SND and/or AVB suitable for CNA and discontinuation of PM and TLE therapy. In addition, blood samples will be collected for future analysis and biobanking. Methodology Inclusion criteria Patients up to 50 years old who underwent pacemaker implantation due to sinus node and/or atrioventricular node dysfunction Positive response to atropine test Age between 18-65 years Signed informed consent to participate in the study Exclusion criteria Own heart rate <30/min Fainting after pacemaker therapy initiation Persistent and sustained atrial fibrillation History of myocarditis History of cardiac surgery History of ablation procedures Congenital heart defects Congenital atrioventricular block Neuromuscular and neurodegenerative diseases Indications for expanding the pacemaker system to ICD/CRT-D Pregnancy Renal insufficiency with GFR <30 ml/min/1.73m2 Randomization, study scheme Qualified patients will be randomly assigned (1:1:1) to group 1 undergoing first-stage invasive electrophysiology study (EPS), extracardiac vagus nerve stimulation (ECVS) and CNA with continued PM therapy and implantable loop recorder (ILR) implantation, to group 2 undergoing first-stage EPS and ECVS with continued PM therapy, ILR implantation, and no CNA, and to group 3 where patients will undergo observation only for the entire study period. The follow-up time will be 18 months. Groups 1 and 2 will be blinded. Two months after the first invasive procedure, the secondary endpoint-stimulation rate in all groups will be assessed. In addition, a non-invasive evaluation of the efficacy of CNA and the incidence of syncope (MAS) and collapse (paraMAS) will take place in group 1, as well as an evaluation of the pacing percentage. After another month during the second hospitalization, the following will be performed: EPS and ECVS, and repeat CNA if ECVS does not show full parasympathetic cardiac denervation. In group 2, after 2 months, non-invasive tests will also be performed to assess and presence of MAS, paraMAS symptoms, and to assess pacing rates. After another month, during the second hospitalization, the following will be performed: EPS, ECVS and CNA. Group 1 and 2 patients with an effective CNA confirmed on ECVS will have their pacemaker set to VVI/AAI 30/min. Group 3 patients will then be evaluated for pacing rates and MAS, paraMAS symptoms. At the third visit, one month after the second invasive procedure in group 1 and 2 patients, the pacing percentage will be assessed. Patients with zero pacing percentage PM will be put on ODO/OVO/OAO-pacing off mode. Patients with a pacing percentage greater than zero PM will be set to their optimal mode. A pacing percentage of <0.1% will be treated as 0%, which will be confirmed in the ILR control. For the next 12 months, patients will be observed. During this period, at the next 4 visits repeated every 3 months, groups 1 and 2 will undergo a non-invasive assessment of CNA efficacy and bradycardia symptoms, while group 3 will be evaluated for MAS, paraMAS and pacing percentage assessment. At the 7th visit, the qualification of patients in groups 1 and 2 for discontinuation of continued pacing treatment will take place, with possible qualification for TLE. Justification Early and late results of a new strategy which is CNA, indicate the possibility of developing an new approach that allows patients with functional bradycardia to decide whether to discontinue or optimize PM therapy. However, standardized approaches based on noninvasive and invasive techniques have not yet been validated and evaluated in a prospective, multicenter, randomized, controlled trial with long-term remote follow-up, including ILR.
Detailed Description
Visit 1- Screening, recruitment, randomization. ECG, PM check, NIEPS change the stimulation mode to DDD 50/min, AV 220ms/ VVI 50/min/ AAI 50/min atropine test laboratory tests: complete blood count, creatinine, AST, ALT, TSH, fT3, fT4, NT-proBNP, beta-HCG, K analysis of inclusion and exclusion criteria Hospitalization 1-1 month from randomization Group 1- EPS, ECVS, CNA, ILR implantation Group 2- EPS, ECVS, ILR implantation Group 3- observation Visit 2-3 months after randomization Group 1 and 2: History of MAS and paraMAS symptoms and the consequences of the procedures performed. PM control with the assessment of the percentage of stimulation. Change settings and check PM - to assess the efficiency of own rhythm, patients will then have their pacemaker reprogrammed in DDD 50/min mode with AV 220ms or VVI 50/min. or AAI 50/min. ECG NIEPS 24-hour Holter ECG monitoring ILR control Group 3 observation: History of MAS and paraMAS symptoms. PM control with the assessment of the percentage of stimulation. Hospitalization 2-4 months from randomization Group 1 - EPS, ECVS, redo CNA if required Group 2 - EPS, ECVS, CNA In patients with confirmed effective CNA groups 1 and 2, the PM will be reprogrammed into the mode. AAI/VVI 30/min For patients of Groups 1 and 2 in whom the CNA proved to be ineffective, the PM will be programmed in the optimal mode for them. Visit 3-6 months after randomization Group 1 and 2: History of MAS and paraMAS symptoms and the consequences of the procedures performed. PM control with the evaluation of the percentage of stimulation. Changing settings and checking PM- to assess the efficiency of your own rhythm ECG NIEPS 24 hour Holter ECG monitoring ILR control Patients from groups 1 and 2, whose percentage of stimulation in PM control will be 0%, will have their PM reprogrammed to ODO/OVO/OAO - pacing off. Group 3 observation: History of MAS and paraMAS symptoms. PM control with the assessment of the percentage of stimulation. Visits 4, 5, 6 - consecutively 9, 12, 15 months after randomization Groups 1 and 2: Anamnesis for possible symptoms of bradycardia and undesirable effects of the procedure. PM control ECG NIEPS 24-hour Holter ECG monitoring ILR control Patients in Groups 1 and 2 who experience symptoms of bradycardia correlated with bradycardia recorded in the ILR will resume pacing in the optimal mode for them. During these visits, patients in Group 3 and Groups 1 and 2 who had their pacing restored/optimized will be interviewed for possible MAS and paraMAS symptoms, perform a physical examination, and check the PM with assessment of pacing percentage and pacing mode optimization. Visit 7 - ending the study - 18 months from randomization. Group 1 and 2: Anamnesis for possible symptoms of bradycardia and undesirable effects of the procedure. PM control ECG NIEPS Atropine test 24-hour Holter ECG monitoring ILR control Patients from groups 1 and 2 without symptoms of bradycardia and without asymptomatic bradycardia <40/min recorded in the ILR, after assessment by the EP-HEART TEAM (a council of two cardiologist specialists), will be qualified for the end of permanent pacing therapy. Those patients with a low risk of TLE will be qualified for TLE. During this visit, Group 3 and Group 1 and 2 patients with previously pacing restored/optimized will be interviewed for possible MAS and paraMAS symptoms, perform a physical examination and PM check with assessment of pacing percentage and pacing mode optimisation. The ILR will be left in place until the battery runs out or will be removed sooner at the patient's request.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bradycardia, Syncope
Keywords
cardioneuroablarion, functional bradycardia, pacemaker treatment discontinuation

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
The project is a double-blind study. Blinding will only apply to the study arms with group 1 and 2. Neither the researcher (doctor) nor the participant (patient) will know what invasive procedures will be performed on a given patient. Patients, investigators, and everyone involved in conducting or analyzing the study, along with other persons interested in the results of the study, will remain blinded to the treatment assigned to individual patients (CNA with continuation of PM therapy vs. continuation of PM therapy without CNA) from the beginning of the study until the database is closed. The operator performing EPS, ECVS, CNA and ILR implantation will not be blinded. Operator will not be involved in the subsequent management of the patient in the study.
Allocation
Randomized
Enrollment
99 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Group 1
Arm Type
Experimental
Arm Description
Group 1 will undergo EPS, ECVS, CNA with continuation of PM therapy and ILR implantation. Two months later pacing rate, will be assessed. In addition, there will be a non-invasive assessment of the effectiveness of CNA. After another month, EPS and ECVS will be performed and a re-CNA if the ECVS does not show full parasympathetic denervation of the heart. For patients with ECVS-confirmed successful CNA, the pacemaker will be set to VVI or AAI 30/min. One month after the second invasive procedure, the pacing rate will be assessed. Patients with zero percentage of PM stimulation will be set to ODO/OVO/OAO-stimulation off mode. Patients will be monitored for the next 12 months. During the next 4 visits repeated every 3 months, patients in this group will undergo non-invasive assessment of the effectiveness of CNA and symptoms of bradycardia. At the 7th visit, patients in this group will be qualified to discontinue of the cardiac pacing treatment, with possible qualification for TLE.
Arm Title
Group 2
Arm Type
Experimental
Arm Description
Group 2 will undergo EPS and ECVS with continuation of PM therapy, ILR implantation, without CNA. Two months later pacing rate, will be assessed. After another month, EPS, ECVS and CNA will be made. For patients with ECVS-confirmed successful CNA, the pacemaker will be set to VVI or AAI 30/min. One month after the second invasive procedure, patients in this group will have their pacing rate assessed. Patients with zero percentage of PM stimulation will be set to ODO/OVO/OAO-stimulation off mode. Patients will be monitored for the next 12 months. During next 4 visits repeated every 3 months, patients in this group will undergo a non-invasive assessment of the effectiveness of CNA and symptoms of bradycardia. At the 7th visit, the qualification for discontinuation of cardiac pacing treatment will take place, with possible qualification for TLE.
Arm Title
Group 3
Arm Type
Active Comparator
Arm Description
Group 3 patients will only be observed for the duration of the study. The observation period will be 18 months. At subsequent visits 1, 3, 4, 6, 9, 12, 15 months after randomization, they will be assessed for the presence of MAS, paraMAS and assessment of the percentage of stimulation.
Intervention Type
Diagnostic Test
Intervention Name(s)
Invasive electrophysiological study
Other Intervention Name(s)
EPS
Intervention Description
Invasive electrophysiological study consists in inserting two electrodes into the heart through femoral vein puncture into the right atrium and right ventricle. Then the following measurements are taken: SNRT- sinus rhythm recovery time, cSNRT- corrected sinus rhythm recovery time, Wenckebach point, AH and HV time and HRV-rhythm variability after SNRT measurement. The examination will be performed under general anesthesia.
Intervention Type
Diagnostic Test
Intervention Name(s)
Extracardiac vagal stimulation
Other Intervention Name(s)
ECVS
Intervention Description
Extracardiac vagal stimulation consists in leading the electrode through the puncture of the femoral vein, successively to both internal jugular veins and stimulating the vagus nerve at the level of its cranial orifice and lower at the level of the angle of the mandible. Stimulation is performed using the Extra-Cardiac Autonomic NeuroStimulatorPachon. Induction of a sinus pause or AV block during vagal stimulation is considered a positive test result. Absence of sinus pause and AV block during vagal stimulation indicates parasympathetic denervation of the heart. The examination is performed under general anesthesia.
Intervention Type
Procedure
Intervention Name(s)
Cardioneuroablation
Other Intervention Name(s)
CNA
Intervention Description
CNA consists in complete parasympathetic denervation of the heart or in its deep neuromodulation by destroying the postganglionic nerve fibers of the vagus nerve, located in the epicardium in the vicinity of the pulmonary veins to the left atrium and in the area of the interatrial septum. It consists in inserting the electrode into the left atrium through puncture of the femoral vein, and then the interatrial septum, and performing ablation in the vicinity of the pulmonary vein orifices and on the interatrial septum at the level of the mitral annulus. Then the electrode is withdrawn into the right atrium and subsequent applications are made in the area of the coronary sinus opening and the roof of the right atrium and the upper part of the interatrial septum. The procedure is performed under general anesthesia. In group 1, CNA will be performed 1 month after randomization. In group 2, CNA will be performed 4 months after randomization.
Intervention Type
Procedure
Intervention Name(s)
Redo cardioneuroablation
Other Intervention Name(s)
redo CNA
Intervention Description
It consists in re-performing the CNA if full parasympathetic parasympathetic denervation of the heart is not confirmed by ECVS.
Intervention Type
Procedure
Intervention Name(s)
Implantation of the implantable loop recorder
Other Intervention Name(s)
ILR implantation
Intervention Description
Implantation of the implantable loop recorder consists in subcutaneous implantation of the ECG loop recorder in the sternum area.
Intervention Type
Diagnostic Test
Intervention Name(s)
Pacemaker check
Other Intervention Name(s)
PM check
Intervention Description
It consists in evaluating the reliability of the PM system. And the assessment of pacing percentage and recorded arrhythmias. After successful cardioneuroablation in groups 1 and 2, 4 months after randomization, the PM will be programmed to the VVI 30/min mode and after 6 months to the OAO/OVO mode. In group 3 patients and in the case of unsuccessful cardioneuroablation, the pacemaker will be set to the optimal mode for the patient. During the PM control, a non-invasive electrophysiological study (NIEPS) is also performed, in which the SNRT, cSNRT, Wenckebach point and HRV after SNRT measurement are assessed. The procedure will be repeated at subsequent visits 1, 3, 4, 6, 9, 12, 15, 18 months after randomization.
Intervention Type
Diagnostic Test
Intervention Name(s)
Implantable loop recorder check
Other Intervention Name(s)
ILR check
Intervention Description
Assessment of arrhythmias recorded in the ILR. The procedure will be repeated at subsequent visits 3, 4, 6, 9, 12, 15, 18 months after randomization.
Intervention Type
Diagnostic Test
Intervention Name(s)
Holter ECG
Intervention Description
24 hour ECG recording. The procedure will be repeated at subsequent visits 1, 3, 4, 6, 9, 12, 15, 18 months after randomization.
Intervention Type
Diagnostic Test
Intervention Name(s)
Anamnesis
Intervention Description
Medical history assessing symptoms of bradycardia, MAS, paraMAS and complications of performed procedures. The procedure will be repeated at subsequent visits 1, 3, 4, 6, 9, 12, 15, 18 months after randomization.
Primary Outcome Measure Information:
Title
Primary efficacy endpoints- Composite endpoint
Description
Composite endpoint including: occurrence of non-traumatic loss of consciousness occurrence of symptoms of presyncope state determination in the loop recorder recording of events of asymptomatic bradycardia requiring permanent cardiac pacing, understood as: type II degree atrioventricular block and/or atrioventricular block of 2:1 or higher order and/or sinus bradycardia <40/min during the patient's wakefulness sinus pause >3 seconds during the patient's wakefulness
Time Frame
18 months
Title
Primary safety endpoints- Composite endpoint
Description
Composite endpoint including: death from any cause peri-procedural damage to cardiac or vascular structures requiring surgical intervention not resulting in death ischemic stroke not terminated by death symptomatic damage to the pulmonary veins symptomatic injury to the phrenic nerve de-electrode device-related infective endocarditis device lodge infection electrode dysfunction requiring electrode replacement BARC grade 2, 3 bleeding during postoperative anticoagulant therapy
Time Frame
18 months
Secondary Outcome Measure Information:
Title
Secondary efficacy endpoint
Description
Occurrence of non-traumatic loss of consciousness
Time Frame
18 months
Title
Secondary efficacy endpoint
Description
Occurrence of syncope in the course of documented bradyarrhythmia
Time Frame
18 months
Title
Secondary efficacy endpoint
Description
Occurrence of symptoms of pre-fainting state
Time Frame
18 months
Title
Secondary efficacy endpoint
Description
Occurrence of presyncope in the course of documented bradyarrhythmia
Time Frame
18 months
Title
Secondary efficacy endpoint
Description
Determination in the loop recorder recording of events of asymptomatic bradycardia requiring permanent pacing of the heart, understood as: atrioventricular block type II and/or atrioventricular block of 2:1 or higher order and/or sinus bradycardia <40/min during the patient's wakefulness sinus pause >3 seconds during the patient's wakefulness
Time Frame
18 months
Title
Secondary efficacy endpoint
Description
Disabling permanent cardiac pacing at visit 3
Time Frame
18 months
Title
Secondary efficacy endpoint
Description
Demonstration of a statistically significant lower pacing rate in the group of patients undergoing CNA vs patients who continued PM therapy without CAN
Time Frame
18 months
Title
Secondary efficacy endpoint
Description
Qualification for removal of PM and TLE system
Time Frame
18 months
Title
Secondary safety endpoint
Description
Death from any cause
Time Frame
18 months
Title
Secondary safety endpoint
Description
Peri-procedural damage to cardiac or vascular structures requiring surgical intervention not resulting in death
Time Frame
18 months
Title
Secondary safety endpoint
Description
Ischemic stroke not terminated by death
Time Frame
18 months
Title
Secondary safety endpoint
Description
Symptomatic pulmonary venous injury
Time Frame
18 months
Title
Secondary safety endpoint
Description
Symptomatic phrenic nerve injury
Time Frame
18 months
Title
Secondary safety endpoint
Description
Asymptomatic phrenic nerve injury
Time Frame
18 months
Title
Secondary safety endpoint
Description
Electrodermal infective endocarditis
Time Frame
18 months
Title
Secondary safety endpoint
Description
PM implantation site infection
Time Frame
18 months
Title
Secondary safety endpoint
Description
Electrode dysfunction
Time Frame
18 months
Title
Secondary safety endpoint
Description
Occurrence of atrial tachyarrhythmias
Time Frame
18 months
Title
Secondary safety endpoint
Description
Development of symptoms of heart failure
Time Frame
18 months
Title
Secondary safety endpoint
Description
Symptoms of inadequate sinus tachycardia
Time Frame
18 months
Title
Secondary safety endpoint
Description
Hospitalization for any reason
Time Frame
18 months
Title
Secondary safety endpoint
Description
BARC grade 2, 3 bleeding during postoperative anticoagulant therapy
Time Frame
18 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients who underwent pacemaker implantation before 50 years old due to sinus node and/or atrioventricular node dysfunction Positive response to atropine test Age between 18-65 years Signed informed consent to participate in the study Exclusion Criteria: Own heart rate <30/min Fainting after pacemaker therapy initiation Persistent and sustained atrial fibrillation History of myocarditis History of cardiac surgery History of ablation procedures Congenital heart defects Congenital atrioventricular block Neuromuscular and neurodegenerative diseases Indications for expanding the pacemaker system to ICD/CRT-D Pregnancy Renal insufficiency with GFR <30 ml/min/1.73m2
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Przemyslaw Skoczynski, PhD
Phone
48602753043
Email
przemyslaw.skoczynski@umed.wroc.pl
First Name & Middle Initial & Last Name or Official Title & Degree
Bruno Hrymniak, MD
Phone
48603766801
Email
bruno.hrymniak@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Przemyslaw Skoczynski, PhD
Organizational Affiliation
4th Military Clinical Hospital with Polyclinic, Poland
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Dariusz Jagielski, PhD
Organizational Affiliation
4th Military Clinical Hospital with Polyclinic, Poland
Official's Role
Study Director
Facility Information:
Facility Name
Mazowiecki Specialist Hospital
City
Radom
State/Province
Mazowieckie
ZIP/Postal Code
26-617
Country
Poland
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sebastian Stec, Professor
Email
smstec@wp.pl
Facility Name
Medical University of Silesia
City
Katowice
State/Province
Śląskie
ZIP/Postal Code
40-055
Country
Poland
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jacek Bednarek, PhD
Email
kbigosinska@sum.edu.pl

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
34455430
Citation
Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, Barrabes JA, Boriani G, Braunschweig F, Brignole M, Burri H, Coats AJS, Deharo JC, Delgado V, Diller GP, Israel CW, Keren A, Knops RE, Kotecha D, Leclercq C, Merkely B, Starck C, Thylen I, Tolosana JM; ESC Scientific Document Group. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J. 2021 Sep 14;42(35):3427-3520. doi: 10.1093/eurheartj/ehab364. No abstract available. Erratum In: Eur Heart J. 2022 May 1;43(17):1651.
Results Reference
result
PubMed Identifier
31424500
Citation
Rudbeck-Resdal J, Christiansen MK, Johansen JB, Nielsen JC, Bundgaard H, Jensen HK. Aetiologies and temporal trends of atrioventricular block in young patients: a 20-year nationwide study. Europace. 2019 Nov 1;21(11):1710-1716. doi: 10.1093/europace/euz206.
Results Reference
result
PubMed Identifier
34865518
Citation
Chung MK, Fagerlin A, Wang PJ, Ajayi TB, Allen LA, Baykaner T, Benjamin EJ, Branda M, Cavanaugh KL, Chen LY, Crossley GH, Delaney RK, Eckhardt LL, Grady KL, Hargraves IG, True Hills M, Kalscheur MM, Kramer DB, Kunneman M, Lampert R, Langford AT, Lewis KB, Lu Y, Mandrola JM, Martinez K, Matlock DD, McCarthy SR, Montori VM, Noseworthy PA, Orland KM, Ozanne E, Passman R, Pundi K, Roden DM, Saarel EV, Schmidt MM, Sears SF, Stacey D, Stafford RS, Steinberg BA, Youn Wass S, Wright JM. Shared Decision Making in Cardiac Electrophysiology Procedures and Arrhythmia Management. Circ Arrhythm Electrophysiol. 2021 Dec;14(12):e007958. doi: 10.1161/CIRCEP.121.007958. Epub 2021 Dec 6.
Results Reference
result
PubMed Identifier
15670960
Citation
Pachon JC, Pachon EI, Pachon JC, Lobo TJ, Pachon MZ, Vargas RN, Jatene AD. "Cardioneuroablation"--new treatment for neurocardiogenic syncope, functional AV block and sinus dysfunction using catheter RF-ablation. Europace. 2005 Jan;7(1):1-13. doi: 10.1016/j.eupc.2004.10.003.
Results Reference
result
PubMed Identifier
21712276
Citation
Pachon JC, Pachon EI, Cunha Pachon MZ, Lobo TJ, Pachon JC, Santillana TG. Catheter ablation of severe neurally meditated reflex (neurocardiogenic or vasovagal) syncope: cardioneuroablation long-term results. Europace. 2011 Sep;13(9):1231-42. doi: 10.1093/europace/eur163. Epub 2011 Jun 28.
Results Reference
result
PubMed Identifier
36114133
Citation
Piotrowski R, Baran J, Sikorska A, Krynski T, Kulakowski P. Cardioneuroablation for Reflex Syncope: Efficacy and Effects on Autonomic Cardiac Regulation-A Prospective Randomized Trial. JACC Clin Electrophysiol. 2023 Jan;9(1):85-95. doi: 10.1016/j.jacep.2022.08.011. Epub 2022 Aug 28.
Results Reference
result
PubMed Identifier
34639716
Citation
Tulecki L, Polewczyk A, Jachec W, Nowosielecka D, Tomkow K, Stefanczyk P, Kosior J, Duda K, Polewczyk M, Kutarski A. A Study of Major and Minor Complications of 1500 Transvenous Lead Extraction Procedures Performed with Optimal Safety at Two High-Volume Referral Centers. Int J Environ Res Public Health. 2021 Oct 3;18(19):10416. doi: 10.3390/ijerph181910416.
Results Reference
result
PubMed Identifier
32688392
Citation
Sidhu BS, Gould J, Bunce C, Elliott M, Mehta V, Kennergren C, Butter C, Deharo JC, Kutarski A, Maggioni AP, Auricchio A, Kuck KH, Blomstrom-Lundqvist C, Bongiorni MG, Rinaldi CA; ELECTRa Investigators Group. The effect of centre volume and procedure location on major complications and mortality from transvenous lead extraction: an ESC EHRA EORP European Lead Extraction ConTRolled ELECTRa registry subanalysis. Europace. 2020 Nov 1;22(11):1718-1728. doi: 10.1093/europace/euaa131.
Results Reference
result

Learn more about this trial

Comparison of the Efficacy and Safety of Cardioneuroablation to Permanent Pacing in Patients With an Implanted Pacemaker for Symptomatic Bradycardia.

We'll reach out to this number within 24 hrs